These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics. Zhang W; Wang H; Feng N; Li Y; Gu J; Wang Z Antib Ther; 2023 Jan; 6(1):13-29. PubMed ID: 36683767 [TBL] [Abstract][Full Text] [Related]
23. The Therapeutic Antibody Profiler for Computational Developability Assessment. Raybould MIJ; Deane CM Methods Mol Biol; 2022; 2313():115-125. PubMed ID: 34478133 [TBL] [Abstract][Full Text] [Related]
24. Purification of Antibodies Using Affinity Chromatography. Darcy E; Leonard P; Fitzgerald J; Danaher M; Ma H; O'Kennedy R Methods Mol Biol; 2017; 1485():305-318. PubMed ID: 27730559 [TBL] [Abstract][Full Text] [Related]
25. Chromatographic kinetic measurements of human serum albumin adsorption on monoclonal antibodies. Renard J; Vidal-Madjar C; Sebille B; Lapresle C J Mol Recognit; 1995; 8(1-2):85-9. PubMed ID: 7598956 [TBL] [Abstract][Full Text] [Related]
26. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation. Shen Y; Zeng L; Novosyadlyy R; Forest A; Zhu A; Korytko A; Zhang H; Eastman SW; Topper M; Hindi S; Covino N; Persaud K; Kang Y; Burtrum D; Surguladze D; Prewett M; Chintharlapalli S; Wroblewski VJ; Shen J; Balderes P; Zhu Z; Snavely M; Ludwig DL MAbs; 2015; 7(5):931-45. PubMed ID: 26073904 [TBL] [Abstract][Full Text] [Related]
27. Assessing developability early in the discovery process for novel biologics. Fernández-Quintero ML; Ljungars A; Waibl F; Greiff V; Andersen JT; Gjølberg TT; Jenkins TP; Voldborg BG; Grav LM; Kumar S; Georges G; Kettenberger H; Liedl KR; Tessier PM; McCafferty J; Laustsen AH MAbs; 2023; 15(1):2171248. PubMed ID: 36823021 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody. Bond MD; Panek ME; Zhang Z; Wang D; Mehndiratta P; Zhao H; Gunton K; Ni A; Nedved ML; Burman S; Volkin DB J Pharm Sci; 2010 Jun; 99(6):2582-97. PubMed ID: 20039394 [TBL] [Abstract][Full Text] [Related]
30. Determination of tryptophan oxidation of monoclonal antibody by reversed phase high performance liquid chromatography. Yang J; Wang S; Liu J; Raghani A J Chromatogr A; 2007 Jul; 1156(1-2):174-82. PubMed ID: 17379231 [TBL] [Abstract][Full Text] [Related]
31. Ion-pair reversed-phase high performance liquid chromatography method for the quantification of isoaspartic acid in a monoclonal antibody. Kern W; Mende R; Denefeld B; Sackewitz M; Chelius D J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Apr; 955-956():26-33. PubMed ID: 24631807 [TBL] [Abstract][Full Text] [Related]
33. Screening for weak monoclonal antibodies in hybridoma technology. Leickt L; Grubb A; Ohlson S J Mol Recognit; 1998; 11(1-6):114-6. PubMed ID: 10076820 [TBL] [Abstract][Full Text] [Related]
34. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Xu Y; Roach W; Sun T; Jain T; Prinz B; Yu TY; Torrey J; Thomas J; Bobrowicz P; Vásquez M; Wittrup KD; Krauland E Protein Eng Des Sel; 2013 Oct; 26(10):663-70. PubMed ID: 24046438 [TBL] [Abstract][Full Text] [Related]
35. Application of a kosmotrope-based solubility assay to multiple protein therapeutic classes indicates broad use as a high-throughput screen for protein therapeutic aggregation propensity. Yamniuk AP; Ditto N; Patel M; Dai J; Sejwal P; Stetsko P; Doyle ML J Pharm Sci; 2013 Aug; 102(8):2424-39. PubMed ID: 23712759 [TBL] [Abstract][Full Text] [Related]
37. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies. Brader ML; Estey T; Bai S; Alston RW; Lucas KK; Lantz S; Landsman P; Maloney KM Mol Pharm; 2015 Apr; 12(4):1005-17. PubMed ID: 25687223 [TBL] [Abstract][Full Text] [Related]
38. Nanomolar to sub-picomolar affinity measurements of antibody-antigen interactions and protein multimerizations: fluorescence-assisted high-performance liquid chromatography. Rispens T; Ooijevaar-de Heer P; Derksen NI; Wolbink G; van Schouwenburg PA; Kruithof S; Aalberse RC Anal Biochem; 2013 Jun; 437(2):118-22. PubMed ID: 23499975 [TBL] [Abstract][Full Text] [Related]
39. Column chromatography of antibodies and fragments. Smith JA Curr Protoc Immunol; 2001 May; Appendix 3():Appendix 3I. PubMed ID: 18432661 [TBL] [Abstract][Full Text] [Related]
40. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties. Svilenov HL; Arosio P; Menzen T; Tessier P; Sormanni P MAbs; 2023; 15(1):2164459. PubMed ID: 36629855 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]